Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › adenocarcinoma of the gastroesophageal junction

Adenocarcinoma of the gastroesophageal junction

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for adenocarcinoma of the gastroesophageal junction

41 trials tracked for adenocarcinoma of the gastroesophageal junction: 6 in phase 3 or 4 and 5 with published results. The most-cited published study has 721 citations.

41Trials tracked
6Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 3 6 Phase 2 31 Phase 1 3 Other / NA 1
  1. Phase 3 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) Completed · 721 cited
  2. Phase 3 A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer Completed · 289 cited
  3. Phase 3 A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) Completed · 170 cited
  4. Phase 3 Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Completed · 106 cited
  5. Phase 3 A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer Completed · 98 cited
  6. Phase 3 Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer Completed
Show 35 more trials
  1. Phase 2 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer Completed
  2. Phase 2 Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer Completed
  3. Phase 2 A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma Completed
  4. Phase 2 Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction Completed
  5. Phase 2 Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach Completed
  6. Phase 2 A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) Completed
  7. Phase 2 Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery Completed
  8. Phase 2 S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer Completed
  9. Phase 2 Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer Completed
  10. Phase 2 Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer Completed
  11. Phase 2 A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer Completed
  12. Phase 2 Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer Completed
  13. Phase 2 PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy Completed
  14. Phase 2 Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer Completed
  15. Phase 2 Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction Completed
  16. Phase 2 Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma Completed
  17. Phase 2 Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer Completed
  18. Phase 2 Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer Completed
  19. Phase 2 A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer Completed
  20. Phase 2 Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer Completed
  21. Phase 2 Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer Completed
  22. Phase 2 Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery Completed
  23. Phase 2 Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Completed
  24. Phase 2 Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Completed
  25. Phase 2 TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Completed
  26. Phase 2 Perioperative Chemo and Pembrolizumab in Gastric Cancer Completed
  27. Phase 2 Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer Completed
  28. Phase 2 Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis Completed
  29. Phase 2 Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery Completed
  30. Phase 2 Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma Completed
  31. Phase 2 A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer Completed
  32. Phase 1 A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer Completed
  33. Phase 1 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Completed
  34. Phase 1 A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery Completed
  35. N/A 64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer Completed

Showing the 41 most-cited and recently-updated of 41 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Adenocarcinoma of the gastroesophageal junction: what the trials found

Pembrolizumab has demonstrated significant improvements in clinical outcomes for adenocarcinoma of the gastroesophageal junction. In a Phase 3 trial, pembrolizumab showed superior Progression Free Survival (PFS) (10.0 vs. 8.1; p=0.0002), Overall Survival (OS) (20.0 vs. 16.8; p=0.0040), and Objective Response Rate (ORR) (72.6% vs. 60.1%; p=0.00020) 1. However, in another Phase 3 trial involving PD-L1 positive participants, pembrolizumab showed no significant difference in PFS compared to the control (p=0.98358), though a statistically significant improvement in OS was observed (9.1 vs. 8.3; p=0.04205) 3.

Ramucirumab has been evaluated in multiple Phase 3 trials. One study reported an ORR of 41.1% compared to 36.4% and a Disease Control Rate (DCR) of 81.9% versus 76.5% 2. Another trial showed significantly improved Progression Free Survival (PFS) with ramucirumab (4.14 vs. 3.15; p=0.0184) and an ORR of 26.5% vs. 21.9% 5. A third Phase 3 trial evaluating ramucirumab did not show statistically significant differences in PFS or OS compared to the control 22.

Chemotherapy agents such as Carboplatin have been studied, with one study reporting a two-year OS of 63.3% and a two-year PFS rate of 16.7% 13. Another trial using carboplatin showed no significant difference in Disease-free Survival (DFS) or Pathologic Complete Response at surgery compared to control 4.

Recent results — preliminary, needs further review

  • Cisplatin was evaluated in a Phase 2 study 7.
  • VE800 was evaluated in a Phase 2 study 9.
  • TAS 102 was evaluated in a Phase 2 study 11.
  • Bevacizumab was evaluated in a Phase 2 study 12.
  • Oxaliplatin showed no significant difference in complete pathological response among PET/CT non-responders 16.

For the clinician treating this condition

  • Pembrolizumab is associated with statistically significant improvements in PFS, OS, and ORR in certain cohorts 1, though results regarding PFS specifically in PD-L1 positive patients were not statistically significant 3.
  • Ramucirumab has shown evidence of improved PFS and ORR in some trials 5, while other Phase 3 studies did not reach statistical significance for primary endpoints like PFS or OS 22.
  • Chemotherapy options such as Carboplatin have established data regarding two-year survival rates and surgical response, though specific comparisons to standard controls were not significant in all tested cohorts [4, 13].

AI synthesis of 12 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Immune checkpoint inhibitor and chemotherapy combination improves pathological response in gastric adenocarcinoma
Allergy & Immunology Meta-analysis
Immune checkpoint inhibitor and chemotherapy combination improves pathological response in gastric adenocarcinoma Immune therapy combined with chemotherapy improves gastric cancer outcomes
This systematic review and meta-analysis of 74 trials evaluates neoadjuvant and perioperative strategies for locally advanced gastric and ga…
Adding immune checkpoint inhibitors to chemotherapy can significantly improve response rates and survival for patients with advanced stomach…
Frontiers Sep 25, 2026
Spatial immune-ecology framework proposed for gastric and GEJ adenocarcinoma ICI selection
Oncology Guideline
Spatial immune-ecology framework proposed for gastric and GEJ adenocarcinoma ICI selection Spatial Features Help Map Immune Responses in Stomach Cancer
This narrative guideline review proposes a spatial immune-ecology framework for advanced gastric and gastroesophageal junction adenocarcinom…
New research maps how the immune system interacts with stomach and esophageal cancer to help experts understand why some treatments work bet…
Frontiers Sep 13, 2026
CLDN18.2 expression prevalence of 33.99% in patients with gastric and gastroesophageal junction adenocarcinoma
Oncology Meta-analysis
CLDN18.2 expression prevalence of 33.99% in patients with gastric and gastroesophageal junction adenocarcinoma New data shows how many stomach cancer patients have target protein
This meta-analysis of 12,173 patients with gastric or gastroesophageal junction adenocarcinoma identified a pooled prevalence of CLDN18.2 ex…
A large review helps doctors understand how many stomach cancer patients have a specific protein that could be a target for new treatments.
Sep 6, 2026
Spatial immune niches provide a framework for understanding immunotherapy resistance in gastric cancer
Oncology Sys. Review
Spatial immune niches provide a framework for understanding immunotherapy resistance in gastric cancer Spatial Immune Niches May Help Explain Gastric Cancer Treatment Response
This narrative review synthesizes diverse data types to identify spatial immune niches as key determinants of immunotherapy response in gast…
New research into spatial immune niches suggests a way to better understand why some patients with gastric cancer respond to immunotherapy.
Frontiers Aug 5, 2026
Cadonilimab plus chemotherapy improves objective response rate to 0.62 in solid tumor patients
Dermatology Meta-analysis
Cadonilimab plus chemotherapy improves objective response rate to 0.62 in solid tumor patients Meta-analysis shows cadonilimab plus chemo improves outcomes for solid tumors
This systematic review and meta-analysis evaluated cadonilimab in patients with solid tumors, including gastric cancer and cervical non-smal…
A meta-analysis of 1,359 patients found cadonilimab combined with chemotherapy improved response rates and survival for solid tumors includi…
Frontiers May 30, 2026
Envafolimab plus lenvatinib and paclitaxel shows activity in advanced gastric cancer after first-line progression
Oncology Phase II
Envafolimab plus lenvatinib and paclitaxel shows activity in advanced gastric cancer after first-line progression New Drug Combo Gives Hope for Late-Stage Stomach Cancer
This phase II, single-center, open-label trial evaluated envafolimab combined with lenvatinib and albumin-bound paclitaxel in 30 patients wi…
Imagine a patient who has already tried every standard treatment available.
Apr 21, 2026